Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of trametinib in preparation of medicine for preventing and/or treating non-alcoholic hepatitis and/or non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technology, applied in the field of pharmacy, to achieve the effect of less damage, less staining value, and less fat particles

Active Publication Date: 2020-03-13
BEIJING GIGACEUTICALS TECH CO LTD
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, trametinib has not been reported in the prevention and treatment of NAFLD and NASH

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trametinib in preparation of medicine for preventing and/or treating non-alcoholic hepatitis and/or non-alcoholic fatty liver disease
  • Application of trametinib in preparation of medicine for preventing and/or treating non-alcoholic hepatitis and/or non-alcoholic fatty liver disease
  • Application of trametinib in preparation of medicine for preventing and/or treating non-alcoholic hepatitis and/or non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Trametinib was tested for activity in the mouse MCD model (NASH model):

[0061] Experimental methods: (1) 8-week-old C57BL / 6N were kept under environmental control, and had free access to standard feed and water. After adapting the mice for one week, they were divided into four groups. The mice in the normal group were fed with normal feed, and the mice in the model group and the mice in the treatment group (low dose, high dose) were fed with methionine choline-deficient feed (MCD, A02082002B).

[0062] After feeding MCD for two weeks, mice in the administration group were injected intraperitoneally with a vehicle (0.5% sodium carboxymethylcellulose (CMC-Na, Sigma) once a day for 14 consecutive days, and mice in the model group and the normal group were small. Rats were injected vehicle with the same frequency.After 14 days, the mice were sacrificed, and the body weight and liver tissue of the mice were weighed.

[0063] Sections of individual livers were fixed with 4...

Embodiment 2

[0069] Trametinib was tested for activity on a mouse high-fat diet / fructose model (NASH model):

[0070] Experimental method: 8-week-old C57BL / 6N were divided into three groups after adapting to the new environment for one week. The normal group was fed with normal diet, and the mice in the model group and the treatment group were fed with high-fat diet (HFD) for eight weeks.

[0071] The normal control group was given normal drinking water and normal feed, the mice in the model group and the mice in the treatment group were given high fructose and high glucose drinking water (23.1g fructose and 18.9g glucose were added to 1L of water) and continued to be given high After 8 weeks of fat-feeding, mice in the administration group were injected intraperitoneally with a vehicle (0.5% carboxymethylcellulose sodium (CMC-Na, Sigma) (Trametinib) by body weight once a day for consecutive 14 days. The dosage is 0.1mg / kg), and the model group and the normal group mice are injected with v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of trametinib in preparation of a medicine for preventing and / or treating non-alcoholic hepatitis, and also provides an application of trametinib in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease. The invention provides the application of trametinib in preparation of the medicine for preventing and / or treating non-alcoholic hepatitis and non-alcoholic fatty liver diseases. The results show that the trimeltinib can effectively reduce ALT, AST, CHO and TG values in an MCD model and reduce liver indexes, the dyeingsurface value of a trimeltinib treatment group is small, fat particles disappear, and inflammatory necrosis is realized; the trimeltinib can effectively reduce fat and inflammatory response in a highfat / fructose model, the dyeing surface value of the trimeltinib treatment group is small, fat granules are obviously reduced, and damage is small.

Description

technical field [0001] The invention belongs to the field of pharmacy, and particularly relates to the application of trametinib in the preparation of prevention and / or treatment of non-alcoholic hepatitis and / or non-alcoholic fatty liver disease. Background technique [0002] With the improvement of living standards, non-alcoholic fatty liver disease (NAFLD) affects the health of more and more people. Nonalcoholic fatty liver disease (NAFLD) refers to the condition of excess fat in the liver in people who drink little or no alcohol. The most common form of NAFLD is a non-serious condition called hepatic steatosis (fatty liver), in which fat builds up in liver cells: although this is not normal, it probably does not damage the liver by itself. NAFLD occurs most often in individuals with a cluster of risk factors known as the metabolic syndrome, which is characterized by elevated fasting blood sugar, or intolerance to blood sugar after meals, being overweight or obese, high ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61P1/16
CPCA61K31/519A61P1/16
Inventor 王靖翔刘祖瑞高明景
Owner BEIJING GIGACEUTICALS TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com